These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38187104)

  • 41. The Effects of Preoperative (18)F-FDG PET/CT in Breast Cancer Patients in Comparison to the Conventional Imaging Study.
    Choi YJ; Shin YD; Kang YH; Lee MS; Lee MK; Cho BS; Kang YJ; Park JS
    J Breast Cancer; 2012 Dec; 15(4):441-8. PubMed ID: 23346174
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Additional value of F-18 FDG PET/CT for initial staging in breast cancer with clinically negative axillary nodes.
    Jeong YJ; Kang DY; Yoon HJ; Son HJ
    Breast Cancer Res Treat; 2014 May; 145(1):137-42. PubMed ID: 24682676
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of US, MRI, and F-18 FDG-PET/CT for Detecting Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Breast Cancer Patients.
    Turan U; Aygun M; Duman BB; Kelle AP; Cavus Y; Tas ZA; Dirim AB; Irkorucu O
    Diagnostics (Basel); 2021 Dec; 11(12):. PubMed ID: 34943597
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnostic performance of
    Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
    Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Diagnostic and prognostic value of (18)F-FDG PET/CT for axillary lymph node staging in patients with breast cancer.
    Kitajima K; Fukushima K; Miyoshi Y; Katsuura T; Igarashi Y; Kawanaka Y; Mouri M; Maruyama K; Yamano T; Doi H; Yamakado K; Hirota S; Hirota S
    Jpn J Radiol; 2016 Mar; 34(3):220-8. PubMed ID: 26715510
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
    Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H
    Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients.
    Straver ME; Aukema TS; Olmos RA; Rutgers EJ; Gilhuijs KG; Schot ME; Vogel WV; Peeters MJ
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1069-76. PubMed ID: 20130860
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessing
    Sarikaya I; Sarikaya A
    J Nucl Med Technol; 2019 Jun; 47(2):149-153. PubMed ID: 30413593
    [No Abstract]   [Full Text] [Related]  

  • 49. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
    Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD
    J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.
    Riegger C; Herrmann J; Nagarajah J; Hecktor J; Kuemmel S; Otterbach F; Hahn S; Bockisch A; Lauenstein T; Antoch G; Heusner TA
    Eur J Nucl Med Mol Imaging; 2012 May; 39(5):852-63. PubMed ID: 22392069
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cervical ultrasonography has no additional value over negative
    Goense L; Meziani J; van Rossum PSN; Wessels FJ; Lam MGEH; van Hillegersberg R; Ruurda JP
    Eur Radiol; 2018 May; 28(5):2031-2037. PubMed ID: 29218619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
    Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
    Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of fluorine-18-labeled 2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography in the evaluation of axillary lymph node involvement in operable breast cancer in comparison with sentinel lymph node biopsy.
    Challa VR; Srivastava A; Dhar A; Parshad R; Bal C; Mohan Reddy Gona R; Kumar R; Datta Gupta S; Sharma P
    Indian J Nucl Med; 2013 Jul; 28(3):138-43. PubMed ID: 24250021
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.
    Rousseau C; Devillers A; Campone M; Campion L; Ferrer L; Sagan C; Ricaud M; Bridji B; Kraeber-Bodéré F
    Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1029-36. PubMed ID: 21308372
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer.
    Barranger E; Grahek D; Antoine M; Montravers F; Talbot JN; Uzan S
    Ann Surg Oncol; 2003 Jul; 10(6):622-7. PubMed ID: 12839846
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer.
    Kumar R; Zhuang H; Schnall M; Conant E; Damia S; Weinstein S; Chandra P; Czerniecki B; Alavi A
    Nucl Med Commun; 2006 Mar; 27(3):231-6. PubMed ID: 16479242
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of nodal staging between CT, MRI, and [
    Morawitz J; Bruckmann NM; Dietzel F; Ullrich T; Bittner AK; Hoffmann O; Ruckhäberle E; Mohrmann S; Häberle L; Ingenwerth M; Abrar DB; Sawicki LM; Breuckmann K; Fendler WP; Herrmann K; Buchbender C; Antoch G; Umutlu L; Kirchner J
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):992-1001. PubMed ID: 34476552
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Value of
    de Mooij CM; Mitea C; Mottaghy FM; Smidt ML; van Nijnatten TJA
    EJNMMI Res; 2021 Nov; 11(1):116. PubMed ID: 34807395
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The predictive value, sensitivity, specificity, and accuracy of PET CT in the evaluation of axillary metastases in breast cancer.
    Cetindag Ö; Avsar G; Hakseven M; Deryol R; Ertekin SÇ; Karasoy D; Eroglu A; Bayar S
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10008-10015. PubMed ID: 37916371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.